KCT0009439尚未招募Unknown
A prospective, open-label, Randomized observational study to evaluate the Efficacy and Safety of remimazolam in patienTs undergoing EndoBronchial Ultrasound-guided TransBronchial Needle Aspiration: REST study
Yeongnam University Medical Center0 个研究点目标入组 330 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Adult males and females aged 19 and above
- •2) ASA 1-3
- •3) BMI 18.5~30.0
- •4) SpO2 = 90% in ambient air or with no more than 2L/min of O2 support
- •5) Patients who can comply with the procedures according to this clinical study protocol and who have voluntarily signed the consent form themselves ,
排除标准
- •1)Patients undergoing both Radial EBUS and ENB simultaneously
- •2)ASA 4 or higher
- •3)Mallampati score 4
- •4)BMI < 18.4, BMI >30.0
- •5)Known sensitivity to benzodiazepines, flumazenil, opioids, naloxone, or a medical condition in which these agents
- •6)Bronchoscopy outside the bronchoscopy unit
- •7)CKD on dialysis
- •8)Patients with a current active acute infection or uncontrolled chronic inflammatory lung disease
- •9)Patients considered inappropriate for the study at the investigator's discretion
研究者
相似试验
Unknown
4 期
evaluate the safety and effectiveness of Fixed Dose Combinations of Bupivacaine and Fentanyl epidural injection in post-operative and labour paiCTRI/2020/07/026903Troikaa Pharmaceuticals Ltd
已完成
不适用
Evaluate the intensity and duration of pain of Diclofenac sodium (75 mg/ml bolus)CTRI/2017/07/009097Akums Drugs and Pharmaceuticals12
招募中
3 期
A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV)polycythemia veraTo assess the benefit/risk profile of cytoreductive therapy with phlebotomy and/or hydroxyurea (HU) aimed at maintaining hematocrit (HCT) < 45% Vs. maintaining HCT in the range of 45-50% in patients with PV treated at the best of recommended therapies (e.g., low dose of aspirin when indicated and adequated control of standard cardiovascular risk factors)Blood - Haematological diseasesACTRN12609000046202Consorzio Mario Negri Sud1,000
已完成
不适用
CLBS12-P01Patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) and patients with CLI due to Buerger's Disease (BD)JPRN-jRCT1080223694EPS Corporation (Global Sponsor: Caladrius Biosciences, Inc.)35
已完成
不适用
A prospective, open label, randomized, controlled trial of tocilizumab versus cyclophosphamide in patients with microscopic polyangiitisMicroscopic polyangiitisJPRN-UMIN000011244Saitama Medical Center, Saitama Medical University Department of Rheumatology and Clinical Immunology40